Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 2/20 | 0.70 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.66 |
| ▸ | ALPI | P09923 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | XIAP | P98170 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | GRB2 | P62993 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21690013 | 1.00 | TPH1 (0.70) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL668746 | 1.00 | TPH1 (0.70) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL31688806 | 0.95 | TPH1 (0.64) | TPH1SLC7A5PTGS1ALPIPKM | |
| Terephthalamide SCHEMBL28537549 | 0.93 | SLC7A5 (0.79) | TPH1SLC7A5PTGS1ALPIPKM | |
| Terephthalamic Acid SCHEMBL28724671 | 0.88 | SLC7A5 (0.71) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL2310526 | 0.88 | SLC7A5 (0.83) | TPH1SLC7A5PTGS1ALPIPKM | |
| Phenylalanine SCHEMBL7110128 | 0.87 | SLC7A5 (0.65) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL29078540 | 0.87 | SLC7A5 (0.65) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL19295504 | 0.86 | SLC7A5 (0.69) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL157002 | 0.86 | SLC7A5 (0.69) | TPH1SLC7A5PTGS1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4613761-A9 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4613761-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | claimed |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | claimed |
| EP-3169403-B9 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | claimed |
| US-20240199700-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-06-20 | — | — | US | claimed |
| EP-4378536-A2 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | Protagonist Therapeutics, Inc. (US) | 2024-06-05 | — | — | EP | claimed |
| US-20240150405-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-05-09 | — | — | US | claimed |
| US-20240132558-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-04-25 | — | — | US | claimed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | claimed |
| EP-4090670-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| EP-4090669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| CN-115298196-A | Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-04 | — | — | CN | claimed |
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-08-11 | — | — | US | claimed |
| EP-3997105-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Protagonist Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| CN-108348580-B | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | 领导医疗有限公司 | 2022-05-10 | — | — | CN | claimed |
| US-10266566-B2 | Protease-resistant peptide ligands | NORTH CAROLINA STATE UNIVERSITY (US) | 2019-04-23 | — | — | US | claimed |
| CN-1133648-C | Substituted phenylalanine-type compounds that inhibit VLA-4 mediated leukocyte adhesion | ������˹ҩƷ��˾ | 2004-01-07 | — | — | CN | claimed |
| CN-1265668-A | Substituted phenylalanine-type compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | TPH1 3586/4885SLC7A5 3470/4885PTGS1 908/4885 |
| US-20240199700-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | TPH1 3950/4885SLC7A5 3281/4885PTGS1 789/4885 |
| US-20240132558-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | TPH1 3586/4885SLC7A5 3470/4885PTGS1 908/4885 |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | TPH1 3586/4885SLC7A5 3470/4885PTGS1 908/4885 |
| US-20240150405-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | TPH1 3586/4885SLC7A5 3470/4885PTGS1 908/4885 |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | TPH1 3586/4885SLC7A5 3470/4885PTGS1 908/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | TPH1 853/4885SLC7A5 1439/4885PTGS1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.